Bellecapital International Ltd. Has $1.22 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Bellecapital International Ltd. lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 14.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,351 shares of the company’s stock after selling 1,194 shares during the quarter. Bellecapital International Ltd.’s holdings in Johnson & Johnson were worth $1,219,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $4,390,037,000. Raymond James Financial Inc. bought a new position in Johnson & Johnson during the fourth quarter valued at about $1,339,878,000. GAMMA Investing LLC raised its holdings in Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock valued at $1,196,596,000 after acquiring an additional 7,185,977 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company’s stock worth $1,149,536,000 after acquiring an additional 4,559,147 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Johnson & Johnson by 12.3% during the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Raymond James cut their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Finally, Benchmark raised Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Stock Up 0.9%

Shares of JNJ opened at $156.61 on Friday. The company has a market capitalization of $376.82 billion, a P/E ratio of 23.55, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The business’s 50 day simple moving average is $153.69 and its 200-day simple moving average is $153.71. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.32%. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.